Fujian Cosunter Pharmaceutical News

Guangshengtang (300436) Quarterly Report Review: Quarterly Improvement and Waiting for New Product Releases

國聯證券Nov 2, 2018 00:00

Guangshengtang (300436) third quarter report review: Tenofovir increases sales and innovative drugs continue to advance

川財證券Oct 26, 2018 00:00

Comments on Guangshengtang (300436) semi-annual report: continuous growth of R & D investment and positive shift to innovative pharmaceutical companies

川財證券Aug 27, 2018 00:00

Guangshengtang (300436): research and development investment in tenofovir helps the company's high growth.

川財證券Apr 23, 2018 00:00

Guangshengtang (300436) Quarterly report comments: waiting for tenofovir to look forward to next year's performance

東方證券Nov 2, 2017 00:00

Guangshengtang (300436) semi-annual report comments: performance short-term pressure waiting for Fuganding listing volume

西南證券Aug 15, 2017 00:00

Guangshengtang (300436) China News comments: the price reduction of the main varieties affects the continuation of the market expansion of new varieties.

國金證券Aug 15, 2017 00:00

Guangshengtang (300436): tenofovir has a better anti-hepatitis B effect.

西南證券May 31, 2017 00:00

Guangshengtang (300436): tenofovir first imitation approval may significantly improve performance

西南證券May 25, 2017 00:00

Guangshengtang (300436): set sail in the new stage of the development of Tinofovir's first imitating Dust settlement Company.

國金證券May 24, 2017 00:00

Guangshengtang (300436) Comment: Tenofovir's first approval symbol begins a new development process

中投證券May 23, 2017 00:00

Guangshengtang (300436): The blockbuster Tenofovir was approved, and the 17-year results are worth looking forward to

東方證券May 23, 2017 00:00

Guangshengtang (300436): The blockbuster tenofovir ester is approved and is expected to contribute profits to the company or reach an inflection point in performance during the year

安信證券May 23, 2017 00:00

Guangshengtang (300436) Quarterly Report Review: Major Varieties Increase and Price Decline Await New Product Approval Contributing Flexibility

國金證券Apr 18, 2017 00:00

Guangshengtang (300436) Quarterly Report: Increased R&D expenses have led to a decline in profits, increased the share of direct sales, paving the way for tenofovir

東方證券Apr 18, 2017 00:00

广生堂(300436)：现有品种瓶颈制约公司成长 替诺福韦酯有望破除发展桎梏

東吳證券Mar 22, 2017 00:00

Guangshengtang (300436) Annual Report Review: Tender price reduction+increased R&D investment dragged down the company's performance, and the imminent approval of tenofovir ester was huge

方正證券Mar 21, 2017 00:00

Guangshengtang (300436) Annual Report Review: 16-year results meet expectations awaiting tenofovir approval

東方證券Mar 21, 2017 00:00

Guangshengtang (300436) Annual Report Review: Direct Sales Capabilities Continue to Improve R&D Investment Drags Down Performance

國金證券Mar 21, 2017 00:00

Guangshengtang (300436) Annual Report Review: The decline in performance is obvious and the listing of Norfovir is expected to improve significantly

西南證券Mar 21, 2017 00:00